Track record · closed signal

Boston Scientific Corporation (BSX) — closed signal from October 14, 2025

Partial Published before the outcome was known, scored automatically when the window closed on January 12, 2026.

Predicted vs. what happened

BSX price · publication thesis → realized outcomesplit-adjusted
$95.66 Published $110.96 Target $95.72 Window close $105.65 Peak
$94.50 – $96.00Entry zone — fair-value band
$95.66Published — price the day we called it
$110.96Target — the price the thesis aimed for
$105.65Peak — highest point inside the window, not a realized return
$95.72Window close — end-of-window price, context only

What happened

Partial

Reached 65% of the predicted growth at its peak, without hitting the target.

Peak price
$105.65
peak on November 13, 2025 — not a realized return
Peak gain
+10.4%
peak, from the publication price
Window close
$95.72
end-of-window price, context only
Days to target
—
Window
October 14, 2025 – January 12, 2026

The thesis — published October 14, 2025

Predicted growth
+16%
over the measurement window
Target price
$110.96
the price the thesis aimed for
Entry zone
$94.50 – $96.00
the fair-value band we waited for
Price at publication
$95.66
published October 14, 2025
Confidence
74%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Boston Scientific is a solid medical-device maker whose stock recently fell more than seemed fair. A respected rating model now labels it a Strong Buy, and Polen Capital just took a new stake, showing serious investor interest. With many sellers likely out, the shares could rebound as people reset positions before earnings. Some worry the price is rich, but near-term odds look tilted toward a bounce.

Primary drivers

  • Respected model now calls it a Strong Buy, a positive quality signal.
  • Polen Capital started a new stake, showing fresh confidence from big money.
  • The stock dropped fast and looks set for a short-term bounce back.
  • Investors may buy ahead of earnings, nudging the price higher soon.

How it played out

BSX: thesis partly played out, but target was missed

Lyra published BSX at 95.66 on 2025-10-14 with a short-term thesis for 16% growth. The thesis pointed to a Strong Buy model label, a new Polen Capital stake, a fast prior drop, and possible buying ahead of earnings. The target was 110.96.

Inside the window, BSX rose to a peak of 105.65 on 2025-11-13, a 10.4% gain. It stayed below the target and never reached 110.96. By 2026-01-12, it ended at 95.72. The thesis partly played out, but the full target was missed.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All BSX signals